Comparative efficacy of positron emission tomography and ultrasonography in preoperative evaluation of axillary lymph node metastases in breast cancer

Breast Cancer. 2000 Jan;7(1):99-103. doi: 10.1007/BF02967197.

Abstract

Purpose: In primary breast cancer, axillary nodal status is the most powerful predictive factor of recurrence. However, axillary lymph node dissection may cause surgical complications. If preoperative evaluation of axillary lymph node metastases is possible, unnecessary axillary lymph node dissections can be avoided. The purpose of this study was to evaluate the efficacy of positron emission tomography (PET) on detection of axillary lymph node metastases in breast cancer.

Methods: PET scans of the axilla were obtained in 32 patients with primary breast cancer. All patients fasted for at least 4 hours before the examination. After transmission scans for attenuation correction were performed, emission scans after intravenous injection of 2-[18F]-fluoro-2-deoxy-D-glucose (FDG) were obtained.

Results: Overall accuracy of PET alone, ultrasonography alone, and in combination in the detection of axillary metastases were 82%, 79%, and 85% respectively.

Conclusion: There were no significant differences between PET, ultrasonography, and PET in combination with ultrasonography regarding sensitivity, specificity and accuracy in the detection of axillary metastases.

Publication types

  • Comparative Study
  • Evaluation Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Axilla
  • Breast Neoplasms / pathology*
  • Breast Neoplasms / surgery
  • Carcinoma / diagnostic imaging
  • Carcinoma / pathology
  • Carcinoma / secondary*
  • Carcinoma / surgery
  • Female
  • Fluorodeoxyglucose F18*
  • Humans
  • Lymphatic Metastasis / diagnostic imaging*
  • Lymphatic Metastasis / pathology
  • Mastectomy
  • Middle Aged
  • Neoplasm Staging
  • Neoplasms, Multiple Primary
  • Preoperative Care*
  • Radiopharmaceuticals*
  • Sensitivity and Specificity
  • Tomography, Emission-Computed*
  • Ultrasonography

Substances

  • Radiopharmaceuticals
  • Fluorodeoxyglucose F18